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Abstract  
Background: Cancer cachexia is associated with patient outcomes. Objective: To evaluate the effect of 
cachexia on survival among patients with metastatic renal cell carcinoma (mRCC) who received first-
line sunitinib treatment. Patients and methods: Seventy-one patients were retrospectively evaluated. 
Sarcopenia was diagnosed using sex-specific cut-offs for skeletal muscle index (measured using pre-
treatment computed tomography) that were adjusted for body mass index. The modified Glasgow 
prognostic score (mGPS) was measured using C-reactive protein (CRP) and albumin levels (mGPS 2: 
CRP >1.0 mg/dL and albumin <3.5 g/dL; mGPS 1: CRP >1.0 mg/dL; mGPS 0: CRP ≤1.0 mg/dL). 
Progression-free survival (PFS) and overall survival (OS) were analyzed using the Kaplan-Meier 
method and Cox proportional hazard models. Results: Forty-five patients (63.4%) had sarcopenia, with 
53 (74.6%), 10 (14.1%), and 8 (11.3%) patients having an mGPS of 0, 1, and 2, respectively. 
Sarcopenia was associated with significantly inferior PFS and OS, compared to non-sarcopenic 
patients (PFS: 7.6 vs. 18.2 months, p = 0.0004; OS: 22.3 months vs. not reached, p = 0.0019). Higher 
mGPS was associated with inferior PFS and OS (mGPS 0, 1, and 2: PFS = 11.5, 10.9, and 4.12 months, 
p < 0.0001; OS = 47.2, not reached, and 5.28 months, p < 0.0001; respectively). Sarcopenia was an 
independent predictor of shorter PFS (p = 0.0163), and mGPS was an independent predictor of shorter 
OS (p = 0.0012). Conclusion: Sarcopenia and mGPS can predict outcomes among patients with mRCC 
who are receiving first-line sunitinib treatment. 
3 
 
 
Key points 
1) Cachexia has a significant effect on the survival of metastatic renal cell carcinoma patients who 
are receiving sunitinib treatment  
2) Sarcopenia and the modified Glasgow prognostic score predict the survival of metastatic renal 
cell carcinoma patients, regardless of dose-limiting toxicities 
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1. Introduction 
 Frailty among cancer patients is associated with poor patient survival [1], which is likely related to 
frailty being a state of increased vulnerability to stressors, which leads to an increased risk of 
developing adverse health outcomes [2]. Although the precise definition and biological characteristics 
of frailty are not clear, severe weight loss and skeletal muscle wasting (i.e., sarcopenia) are considered 
prominent features of frailty. Sarcopenia is an emerging index of nutritional status that has been studied 
in patients with cancer [3, 4]. As cancer cachexia might affect therapy response and survival, 
sarcopenia has recently been suggested as a significant predicator of outcomes for various cancers [5-
8]. For example, sarcopenia can predict survival among patients with metastatic renal cell carcinoma 
(mRCC), with Sharma et al. [9] describing its value among patients with mRCC who underwent 
cytoreductive nephrectomy, and Fukushima et al. [10] describing its value for predicting overall 
survival (OS) among patients with mRCC. Furthermore, Antoun et al. [11], Huillard et al. [12], and 
Mir et al. [13] have reported that the dose-limiting toxicities (DLTs) of tyrosine kinase inhibitors are 
significantly associated with sarcopenia. In this context, sarcopenia is typically defined using the 
cross-sectional areas of the lumbar skeletal muscle, and this definition was established using pre-
treatment imaging in a Canadian cohort study [14]. 
Another marker of the malignancy-induced systematic inflammatory response is the modified 
Glasgow prognostic score (mGPS), which is calculated using levels of C-reactive protein (CRP) and 
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albumin. The mGPS is an independent predictor of patient outcomes [15, 16], and several studies have 
also reported that a similar inflammation-based score is effective in predicting outcomes from renal 
cancers [16-18] . Unfortunately, these tumor and host responses can lead to involuntary progressive 
weight loss or nutritional impairment, which may affect the patient’s performance status and quality 
of life. Although sarcopenia or mGPS, as indexes of cancer cachexia, are useful for predicting patient 
survival in renal cancers, few studies have evaluated whether cachexia affects outcomes among 
patients with mRCC who are receiving first-line sunitinib (SU), which is a first-line molecular targeted 
agent [19-21]. Therefore, this study aimed to examine whether cachexia (as measured using sarcopenia 
and mGPS) could predict survival, as well as SU safety and tolerability among patients with mRCC 
who were receiving first-line SU treatment. 
  
2. Patients and Methods 
 The Internal Ethics Review Board of Tokyo Women’s Medical University approved this retrospective 
study (ID: 3654), which was performed in accordance with the tenets of the Declaration of Helsinki. 
All patients provided their written informed consent for treatment and the collection of their data. A 
total of 156 patients received first-line tyrosine kinase inhibitor treatment without prior cytokine 
therapy at our department between 2007 and 2014. However, we excluded the patients who received 
sorafenib (n=50), pazopanib (n=7), and axitinib (n=2). Among the remaining 97 patients who received 
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first-line SU, we excluded patients who received abbreviated SU administration during a single cycle 
(n = 3), patients who received hemodialysis or transplant therapy (n = 2), and patients for whom 
detailed pre-treatment information and computed tomography (CT) data were missing (n = 21). As the 
current treatment strategy for mRCC consists of molecular targeted agents [19, 21], we excluded 
patients who had received prior cytokine therapy. Finally, we included 71 patients in this study, and 
extracted their clinical and laboratory data from an electronic database and the patients’ medical 
records (Table 1).  
 
2.1. Imaging methods and evaluation of sarcopenia  
 The cross-sectional area of the lumbar skeletal muscles (including the rectus abdominus; bilateral 
internal, external, and lateral obliques; psoas; quadratus lumborum; and erector spinae) was identified 
using attenuation thresholds of -29 Hounsfield units (HU) to +150 HU via a Toshiba Aquilion 64 
multidetector scanner (Toshiba, Tochigi, Japan). The areas of interest were defined manually at each 
1-mm level, and the values for each level were added together. To calculate the skeletal muscle index 
(SMI), L3 was set as the landmark and the mean value of two consecutive images was computed for 
each patient and normalized for stature: SMI (cm2/m2) = (skeletal muscle cross-sectional area at L3)/ 
height2 [7, 22]. SMI was assessed as a continuous variable, and used as an indicator of whole-body 
muscle mass, based on the finding of a previous study that the total lumber-skeletal muscle cross-
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sectional area was linearly correlated with whole-body muscle mass [23]. To classify the patients as 
sarcopenic and non-sarcopenic, we used sex-specific SMI cut-offs that were stratified according to 
body mass index (BMI): for men with a BMI of <25 kg/m2, the SMI cut-off was < 43 cm2/m2; for men 
with a BMI of > 25 kg/m2, the SMI cut-off was < 53 cm2/m2; and for women, the SMI cut-off was < 
41 cm2/m2 [14]. Martin et al. [14] have also reported BMI-adjusted cut-off values for skeletal muscle 
density (SMD), which we defined as low or high muscle attenuation (MA) : low MA was defined as 
< 41 HU for BMIs of < 25 kg/m2, and as < 33 HU for BMIs of ≥ 25 kg/m2 (no sex-specific differences). 
The CT scans were performed for diagnostic or follow-up purposes within 30 days before the initiation 
of SU treatment. All image analyses were performed by a single investigator (H.I.) who was blinded 
to the other clinical parameters and patient outcomes. 
 
2.2. Defining mGPS  
 We calculated mGPS as previously described [15]: patients with high CRP levels (> 1.0 mg/ dL) and 
low albumin levels (< 3.5 g/ dL) were assigned a score of 2. Patients with high CRP levels (> 1.0 mg/ 
dL) were assigned a score of 1, and patients with CRP levels of ≤1.0 mg/ dL were assigned a score of 
0; albumin levels do not affect a score of 1 or 0. The mGPS for all patients was determined at the time 
of their SU treatment initiation. 
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2.3 Sunitinib treatment and toxicity assessment 
To evaluate SU safety and tolerability, we investigated the associations between sarcopenia and 
mGPS with SU-related adverse events and relative dose intensity (RDI), respectively. At our 
department, we treat our mRCC patients using a 4-week-on/2-week-off (4/2) schedule or a 2-week-
on/1-week-off (2/1) schedule, as described by Kondo et al. [24]. SU treatment was initiated at a dosage 
of 50 mg/day, and was modified based on patient factors. Three factors were considered for reduction 
of the initial dose: (1) age of > 65 years, (2) serum creatinine levels of > 2 mg/dL, and (3) a body 
weight of < 50 kg. If one of these three factors was observed, the initial dose was reduced to 37.5 mg. 
If two of these three factors were observed, the initial dose was reduced to 25 mg. We never reduced 
the initial dose to < 25 mg. The dose was subsequently increased by 12.5 mg until we found the highest 
dose that these patients could tolerate, although this dose never exceeded 50 mg. Toxicity was assessed 
at each visit (every 1-2 weeks during the first cycle), and then monthly according to the patient’s 
condition. Adverse events were graded using the Common Terminology Criteria for Adverse Events 
of the National Cancer Institute, version 4.0. Dose reduction or interruption was performed based on 
the guidelines for SU therapy [25]. The RDI was determined during first cycle and during six cycles 
as the ratio of the cumulative dose that was received during the cycle to 1,400 mg. When SU treatment 
was withdrawn before reaching the sixth cycle due to any cause, the RDI was calculated until the last 
treatment cycle. DLTs were defined as any toxicity leading to a dose reduction, temporary or 
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permanent discontinuation of SU treatment. According to a previous study [12], only DLTs occurring 
during the first cycle were considered in our study. Moreover, we compared the cumulative incidences 
of DLTs according to sarcopenic status and mGPS severity. A cycle of treatment was determined as a 
period of 6 weeks.  
 
2.4. Statistical analysis 
Continuous variables were analyzed using the Mann-Whitney U-test and categorical variables were 
analyzed using the χ2 test or Fisher’s exact test. Progression-free survival (PFS) and OS after first-line 
SU therapy initiation, and cumulative incidence of experiencing DLTs, were calculated using the 
Kaplan-Meier method, and compared using the log-rank test between sarcopenic and non-sarcopenic 
patients, according to mGPS. PFS was defined as the time from first-line SU therapy initiation to the 
date of progression or death from any cause, whichever came first. OS was defined as the time from 
first-line SU therapy initiation to death from any cause. Univariate and multivariate analyses were 
used to identify factors that were associated with PFS and OS, via Cox proportional hazards regression 
models. Risk was expressed as hazard ratios (HR) and 95% confidence intervals (CI). All analyses 
were performed using JMP software (version 11; SAS Institute Inc., Cary, NC, USA), and differences 
were considered statistically significant at a p-value of <0.05. 
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3. Results 
3.1. Patient characteristics 
 The patients’ characteristics are shown in Table 1. Sarcopenia was diagnosed in 45 patients (63.4%), 
and the sarcopenic patients were significantly older (mean age: 65.5 years vs. 61.0 years, p = 0.0194) 
and significantly more likely to be female (42.2% vs. 7.69%, p = 0.0025). Furthermore, sarcopenic 
patients exhibited a significantly higher rate of having multiple metastases (64.4% vs. 38.5%, p = 
0.048), and a higher rate of hypoalbuminemia (3.90 g/dL vs. 4.38 g/dL, p < 0.0001). Moreover, 
sarcopenic patients exhibited significantly lower BMI (mean BMI: 22.9 kg/m2 vs. 24.9 kg/m2, p = 
0.0431), skeletal muscle area (96.2 cm2 vs. 139.7 cm2, p < 0.0001), and SMI (36.6 cm2/m2 vs. 50.7 
cm2/m2, p < 0.0001). However, there were no significant differences in the remaining characteristics 
(pathology, radical nephrectomy, Karnofsly perforemance status, time from diagnosis to treatment, 
MSKCC risk, pT stage, eGFR, or serum CRP level at SU treatment initiation; all, p > 0.05). There was 
no significant difference in the two groups’ SMD values (p = 0.197), although a marginal difference 
was observed in their mGPS (p = 0.0534). Sarcopenic patients had a significantly shorter mean follow-
up period (16.0 months vs. 27.4 months, p = 0.0012). 
 
3.2. Patient survival according to sarcopenia status 
 During this follow-up period, progression disease (PD) was observed in 50 patients (70.4%), and 
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27 patients (38.0%) died due to cancer, including one patient who died due to a raptured aortic 
aneurysm. Because many patients in this study died due to cancer, we evaluated OS rather than cancer-
specific survival. Figures 2 and 3 show the Kaplan-Meier survival curves for PFS and OS after SU 
treatment initiation according to sarcopenia status. Sarcopenia was associated with a significantly 
shorter median PFS (7.6 months vs. 18.2 months, p = 0.0004) and median OS (22.3 months vs. not 
reached, p = 0.0019). 
 
3.3. Patient survival according to mGPS  
Figures 4 and 5 show the Kaplan-Meier survival curves for PFS and OS after SU treatment initiation 
according to mGPS. The magnitude of the mGPS was significantly associated with median PFS (score 
0: 11.5 months, score 1: 10.9 months, score 2: 4.12 months; p < 0.0001) and median OS (score 0: 47.2, 
score 1: not reached, score 2: 5.28 months, p < 0.0001). 
 
3.4. Prognostic indicators for patient survival  
 In the univariate analysis, the significant predictors of PFS and OS were sarcopenia, mGPS, 
pathological diagnosis, Karnofsky performance status, time to diagnosis to treatment, MSKCC risk, 
metastatic sites, and pT stage (Table 2). In the multivariate analysis, sarcopenia was an independent 
predictor of shorter PFS (HR: 2.54, p=0.0163), and mGPS was an independent predictor of shorter OS 
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(p=0.0012), altogether with pathological findings (HR: 4.27, p=0.0173). 
 
3.5. Sunitinib safety and tolerability according to sarcopenia and mGPS 
The comparisons between sarcopenic patients and non-sarcopenic patients, and between patients with 
mGPS 0 and those with mGPS 1 and 2 are summarized in Tables 4 and 5. No significant differences 
were found regarding the initial dose, RDI during first cycle, DLTs, or prevalence of toxicities 
according to both sarcopenic status, and mGPS (all p > 0.05). After experiencing DLTs (n=36), we 
observed 31 cases of dose reduction (86.1%), 4 cases of discontinued treatment (11.1%), and 1 case 
of switching to other targeted agents (2.78%). We did not observe any significant differences when we 
performed subanalyses of these outcomes according to sarcopenic status or mGPS severity 
(sarcopenia: p = 0.194, mGPS: p = 0.763). SU treatment was withdrawn before the 2nd, 3rd, 4th, 5th, 
and 6th cycles for 4, 6, 7, 11, and 2 patients, respectively. Sarcpenic status or mGPS severity exhibited 
no significant influence in the long-term RDI (sarcopenia: p = 0.302, mGPS: p = 0.774). Moreover, 
there were no significant differences in the cumulative incidences of experiencing DLTs according to 
sarcopenic status (p = 0.741) or mGPS severity (p = 0.164) (Figure 6, 7). 
 
4. Discussion 
 To our best knowledge, this retrospective study is the first to evaluate the associations of sarcopenia 
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and mGPS (as indicators of cancer cachexia) with survival among patients with mRCC who were 
receiving first-line SU treatment without prior cytokine therapy. Our data indicate that sarcopenia was 
an independent predictor of PFS, whereas mGPS was an independent predictor of OS. Moreover, there 
were no significant differences in SU safety or tolerability between sarcopenic patients and non-
sarcopenic patients, and between patients with mGPS 0 and those with mGPS 1 and 2. 
Our analysis revealed that mGPS significantly predicted OS, which confirms a large cohort study’s 
findings that higher mGPS scores were associated with shorter OS and cancer-specific survival 
(independent of the tumor site) [16]. Furthermore, Lamb et al. [17] have reported that mGPS was at 
least equivalent to, and independent of, other validated prognostic models for predicting survival 
among patients with RCC who were undergoing curative nephrectomy. Thus, mGPS is an independent 
and strong predictor of patient outcomes. Ramsey et al. [18] have suggested that GPS (the 
inflammation-based prognostic score that preceded mGPS) compared favorably with, and was 
independent of, the MSKCC scoring system. In contrast, our findings indicate that the MSKCC risk 
was not an independent predictor of OS, although this discrepancy might be related to differences in 
the patients’ characteristics. Meanwhile, non-CCC was a significant predictor of OS, altogether with 
mGPS in our analysis. This finding confirms a previous study’s hypothesis that non-CCC is a risk 
factor for inferior patient survival [26]. 
 SMD is closely related to muscle lipid content and muscle function, and it is also linked to 
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inflammatory processes [27]. Interestingly, a Canadian study has revealed that SMD was a significant 
predicator of cancer patients’ outcomes [14], and Antoun et al. [22] have also reported that low SMD 
was associated with inferior PFS and OS among patients with mRCC who were receiving several 
kinds of targeted agents. However, we did not observe any significant association between SMD and 
patient outcomes, and another Japanese group has also reported no significant association between 
SMD and OS among patients with mRCC [10]. This discrepancy might be related to the patients’ 
ethnicity or the studies’ sizes, and further large-scale studies are needed to confirm the value of SMD 
for predicting outcomes among patients with mRCC.  
The mechanism by which a systematic inflammatory response may influence survival among cancer 
patients remains unclear. However, CRP is produced in the liver and is strongly induced by cytokines, 
and especially by interleukin-6 (IL-6). Experimental studies have demonstrated that RCC cells can 
produce IL-6, and that IL-6 itself is recognized as a growth promoter in RCC cells [28-31]. 
Furthermore, the increased protein degradation during sarcopenia is induced by catabolic drivers, such 
as systematic inflammation, and sarcopenia itself is considered to be driven by a decrease in protein 
synthesis and an increase in protein degradation [32]. Schaap et al.[33] have suggested that higher 
levels of CRP and IL-6 are significantly associated with the loss of muscle strength, and both the 
systematic inflammatory response and related nutritional decline may influence treatment tolerance 
and compliance [34]. For example, previous studies have demonstrated that sarcopenia is a significant 
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predictor of DLT among patients with mRCC who are receiving SU treatment [12, 35]. Huillard et al. 
[12] described that patients with sarcopenia and a BMI of < 25kg/m2 experienced significantly more 
DLTs during the first cycle of SU treatment, although there was no difference in PFS or OS between 
sarcopenic patients and non-sarcopenic patients. We speculate that these discrepancies were caused by 
differences in the SU treatment regimens. A 2/1 schedule of SU provided a lower incidence of dose 
interruption in our previous study [24], and other studies also reported similar suggestions [36, 37]. 
Moreover, there were more patients receiving 50 mg as an initial dose in Huillard’s study [12] than in 
the present study (49/60 vs. 21/71); our relative lower initial dose might explain the lower rate of early 
DLTs. Moreover, we found that the long-term tolerability of SU treatment was not affected by cachexic 
status, as there were no significant differences in RDI during the six cycles, or in the cumulative 
incidences of DLTs according to sarcopenic status or mGPS severity. Therefore, the results suggest 
that sarcopenia and mGPS were independent predictors of patient survival, regardless of DLTs.  
In this study, no significant differences in DLT or RDI were observed between cachexic and non-
cachexic patients. Moreover, there were no significant differences in the changing of the treatment 
strategy after DLTs, and SU administration was reduced, rather than discontinued, in most patients. 
These results might also be explained by our choice of treatment regimen; the adoption of a 2/1 
schedule might be effective and safe, even for cachexic patients. Meanwhile, other tyrosine kinase, 
such as pazopanib, are suggested as a targeted agent with better safety and quality-of-life profiles, 
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compared to SU [38, 39]. Therefore, when a cachexic patient who is receiving SU experiences a DLT, 
switching to pazopanib may be an effective strategy. Further studies are needed to demonstrate this 
possibility.  
The pharmacokinetics of SU in patients with cachexia remain unknown. Mir et al. [13] report that 
sarcopenia had a significant effect on early DLTs among patients with hepatocellular carcinoma who 
received sorafenib treatment, based on pharmacokinetic measurements. A previous study also reported 
that systematic inflammation has a negative effect on the activity of CYP3A4 [40], which is one of 
the enzymes that is involved in the metabolism of SU. Therefore, it is possible that an unknown 
mechanism could affect survival among patients who are receiving SU, and the effect of cachexia on 
CYP3A4 activity deserves further investigation, which should include phenotype and genotypic 
testing.  
The present study revealed one difference between sarcopenia and mGPS: sarcopenia was only 
associated with PFS, whereas mGPS was only associated with OS. This result is interesting, as both 
sarcopenia and mGPS are similar indicators of cachexia, and we observed a marginal correlation 
between sarcopenia and mGPS (p = 0.0534). Unfortunately, we cannot explain this phenomenon, 
although we speculate that it may be influenced by some interactions between the factors that drive 
sarcopenia and mGPS in the cachexia-induced systematic inflammatory environment. Moreover, we 
found that albumin levels, but not CRP levels, were correlated with sarcopenic status (Table 1). This 
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result is also interesting, as it might mean that sarcopenic status represents a low nutrient condition 
that is induced by systematic inflammation, rather than an inflammatory response. 
There are several limitations in the present study. First, we used a retrospective single-center design 
with a relative small sample size, which may have biased our survival analyses. Second, we were 
unable to retrospectively evaluate weight loss (due to no available data), which is an important 
symptom of cachexia [14, 18]. A further prospective study is needed to evaluate the effect of weight 
loss on survival among patients who are receiving SU treatment. Third, the definitions of sarcopenia 
in this study were based on sex-specific BMI-adjusted Canadian cut-off values for SMI [14], although 
it is possible that these cut-off values may not be appropriate for the Japanese population, due to race-
related differences in physical attributes and muscle mass. Therefore, it may be relevant to identify 
more appropriate cut-off values that are specific to the Japanese population. Fourth, we analyzed the 
cumulative incidence of DLTs using the Kaplan-Meier method, although this method might have 
provided a misleading estimation, based on treatment discontinuation being a possible competing risk.  
In summary, the present study demonstrated that sarcopenia and mGPS were independent predicators 
of survival after initiating first-line SU treatment in patients with mRCC and no prior cytokine therapy, 
regardless of the absence of DLTs, under our alternative treatment regimens. The advantage of these 
parameters is that both sarcopenia and mGPS can be easily evaluated without extra cost or effort, as 
both are quantified using routine CT and blood test findings. Therefore, these parameters might be 
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useful for improving the management of patients with mRCC, although further studies are needed to 
validate our findings. 
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Figure legends  
Figure 1: Patient selection flow-chart. 
  
Figure 2: Progression-free survival after sunitinib treatment initiation according to sarcopenia status. 
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The survival rate was calculated using the Kaplan-Meier method and compared using the log-rank test 
(p = 0.0004). SU: sunitinib   
 
Figure 3: Overall survival after sunitinib treatment initiation according to sarcopenia status. The 
survival rate was calculated using the Kaplan-Meier method and compared using the log-rank test (p 
= 0.0019). SU: sunitinib 
 
Figure 4: Progression-free survival after sunitinib treatment initiation according to mGPS. The 
survival rate was calculated using the Kaplan-Meier method and compared using the log-rank test (p 
< 0.0001). mGPS: modified Glasgow prognostic score; SU: sunitinib   
 
Figure 5: Overall survival after sunitinib treatment initiation according to mGPS. The survival rate 
was calculated using the Kaplan-Meier method and compared using the log-rank test (p < 0.0001). 
mGPS: modified Glasgow prognostic score; SU: sunitinib 
 
Figure 6: Cumulative incidence of experiencing dose-limiting toxicities after sunitinib treatment 
initiation according to sarcopenia status. The cumulative incidence was calculated using the Kaplan-
Meier method and compared using the log-rank test (p = 0.741). SU: sunitinib   
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Figure 7: Cumulative incidence of experiencing dose-limiting toxicities after sunitinib treatment 
initiation according to mGPS. The cumulative incidence was calculated using the Kaplan-Meier 
method and compared using the log-rank test (p = 0.164). SU: sunitinib   
 







Table 1 Table 1: Patient characteristics
All (n = 71) With sarcopenia (n = 45) Without sarcopenia (n = 26) P-value
Sex
Male
Female
50 (70.4%)
21 (29.6%)
26 (57.8%)
19 (42.2%)
24 (92.3%)
2 (7.69%)
0.0025
Mean age at SU treatment initiation, years (median, range) 64.0 (64.0, 31 - 79) 65.6 (64.0, 31 - 79) 61.0 (63.0, 31 - 73) 0.0194
Pathology
CCC
Non-CCC
CCC with spindle cell
CCC with sarcomatoid
PRCC type 2
Medullary carcinoma
Unknown  
58 (81.7%)
13 (18.3%)
3 (4.23%)
1 (1.41%)
5 (7.04%)
1 (1.41%)
3 (4.23%)
34 (75.6%)
11 (15.5%)
2 (4.44%)
1 (2.22%)
4 (8.89%)
1 (2.22%)
3 (6.67%)
24 (92.3%)
2 (7.69%)
1 (3.85%)
0 
1 (3.85%)
0
0
0.0787
Radicalnephrectomy 
Yes
No
64 (90.1%)
7 (9.86%)
39 (86.7%)
6 (13.3%)
25 (96.2%)
1 (3.85%)
0.251
Karnofsky performance status, %
≥ 80
< 80 
64 (90.1%)
7 (9.86%)
40 (88.9%)
5  (11.1%)
24 (92.3%)
2 (7.69%)
0.642
Time from diagnosis to treatment, days
≥ 365 
< 365 
20 (28.2%)
51 (71.8%)
11 (24.4%)
34 (75.6%)
9 (34.6%)
17 (65.4%)
0.418
MSKCC risk
Favorable
Intermediate
Poor
17 (23.9%)
39 (54.9%)
15 (21.1%)
9 (20.0%)
24 (53.3%)
12 (26.7%)
8 (30.8%)
15 (57.7%)
3 (11.5%)
0.267
Number of metastatic sites 
Solitary
Multiple
32 (45.1%)
39 (54.9%)
16 (35.6%)
29 (64.4%)
16 (61.5%)
10 (38.5%)
0.0480
pT stage
pT1-2
pT1a
pT1b
pT2a
pT2b
pT3-4
pT3a
pT3b
pT3c
pT4
21 (29.6%)
5 (7.04%)
6 (8.45%)
7 (9.86%)
3 (4.23%)
50 (70.4%)
27 (38.0%)
10 (14.1%)
6 (8.45%)
7 (9.86%)
11 (24.4%)
3 (6.67%)
3 (6.67%)
3 (6.67%)
2 (4.44%)
34 (75.6%)
19 (42.2%)
5 (11.1%)
5 (11.1%)
5 (11.1%)
10 (38.5%)
2 (7.69%)
3 (11.5%)
4 (15.4%)
1 (3.85%)
16 (61.5%)
8 (30.8%)
5 (19.2%)
1 (3.85%)
2 (7.69%)
0.282
Mean height, m (median, range) 1.63 (1.63, 1.44 - 1.86) 1.61 (1.61, 1.46 - 1.86) 1.66 (1.67, 1.44 - 1.81) 0.0183
Mean Weight, kg (median, range) 63.0 (64.0, 40.0 - 109.0) 59.7 (58.3, 40 - 80.1) 68.6 (67.9, 43 - 109) 0.0030
Mean BMI, kg/m2 (median, range) 23.6 (23.2, 17.8 - 43.7) 22.9 (22.8, 17.8 - 30.7) 24.9 (24.1, 20.7 - 43.7) 0.0431
Mean Skeletalmuscle, cm2 (median, range) 112.1 (112.03, 54.91 - 187.3) 96.2 (95.8, 54.9 - 142.8) 139.7 (137.5, 88.7 - 187.3) <0.0001
Mean SMI, cm2/m2 (median, range) 41.8 (41.8, 24.4 - 66.3) 36.6 (35.8, 24.4 - 48.5) 50.7 (48.9, 42.8 - 66.3) <0.0001
Mean SMD, HU (median, range) 35.7 (33.7, 12.0 - 92.2) 34.2 (33.3, 12.0 - 58.2) 38.5 (35.8, 12.6 - 92.2) 0.197
The mGPS at the time of SU treatment initiation
0 
1 
2 
53 (74.6%)
10 (14.1%)
8 (11.3%)
30 (66.7%)
7 (15.6%)
8 (17.8%)
23 (88.5%)
3 (11.5%)
0 
0.0534
Mean serum eGFR level at SU treatment initiation, mL/min/1.73m2 (median, range) 48.4 (48.5, 12.2 - 88.9) 46.6 (47.4, 12.2 - 72.3) 51.7 (54.5, 19.6 - 88.9) 0.194
Mean serum CRP level at SU treatment initiation, mg/ dL 1.59 (0.39, 0.02 – 15.3) 1.98 (0.56, 0.02 – 15.3) 0.90 (0.24, 0.04 – 7.14) 0.174
Mean serum albumin level at SU treatment initiation, g/ dL 4.08 (4.10, 2.3 – 5.0) 3.90 (4.0, 2.3 – 5.0) 4.38 (4.4, 3.6 – 4.9) <0.0001
Mean follow-up period after SU treatment initiation, months (median, range) 20.2 (17.0, 2.24 - 65.6) 16.0 (13.7, 2.24 - 48.4) 27.4 (23.8, 5.95 - 65.6) 0.0012
SU, sunitinib; CCC, clear cell carcinoma; PRCC, papillary renal cell carcinoma; MSKCC, Memorial Sloan-Kettering Cancer Center; BMI, body mass index; SMI, skeletal muscle index; SMD, skeletal muscle density; HU, Hounsfield unit; mGPS, modified Glasgow prognostic score; eGFR, estimated glomerular filtration rate; CRP, 
C-reactive protein  
Table 2 Table 2: Univariate and multivariate analyses of progression-free survival
Univariate analysis
HR (95% CI)                                    p-value
Multivariate analysis
HR (95% CI)                                                 p-value
Sex
Male
Female
Reference
1.15 (0.61-2.07)
-
0.660
Age 1.00 (0.97-1.03) 0.880
Pathology
CCC
Non-CCC
Reference
2.62 (1.29-5.00)
-
0.0094
Reference
1.82 (0.81-3.93)
-
0.146
Karnofsky performance status, %
≥ 80 
< 80
0.15 (0.066-0.38)
Reference
0.0003
-
0.50 (0.14-1.88)
Reference
0.300
-
Time from diagnosis to treatment, days
≥ 365
< 365
Reference
2.59 (1.34-5.50)
-
0.0038
Reference
0.95 (0.27-6.02)
-
0.942
MSKCC
Favorable
Intermediate
Poor
0.43 (0.18-0.90)
Reference
2.34 (1.18-4.44)
0.0007
0.0251
-
0.0159
0.43 (0.096-3.00)
Reference
1.90 (0.71-4.66)
0.269
0.343
-
0.193
Number of metastatic sites
Solitary
Multiple
Reference
2.04 (1.14-3.73)
-
0.0160
Reference
1.58 (0.77-3.34)
-
0.214
pT stage
pT1-2
pT3-4
Reference
1.91 (1.02-3.83)
-
0.0421
Reference
1.18 (0.56-2.64)
-
0.664
Sarcopenia
No
Yes
Reference
3.15 (1.66-6.41)
-
0.00003
Reference
2.54 (1.19-5.65)
-
0.0163
SMD
High muscle attenuation
Low muscle attenuation
Reference
1.10 (0.62-1.97)
-
0.754
The mGPS
0
1 
2 
0.14 (0.059-0.39)
0.19 (0.063-0.58)
Reference
0.0017
0.0004
0.0045
-
0.71 (0.19-2.71)
0.47 (0.11-2.08)
Reference
0.522
0.614
0.321
-
Serum eGFR level, mL/min/1.73m2 1.00 (0.98-1.02) 0.891
HR, hazard ratio; CI, confidence interval; CCC, clear cell carcinoma; MSKCC, Memorial Sloan-Kettering Cancer Center; SMD, skeletal muscle density; mGPS, 
modified Glasgow prognostic score; eGFR, estimated glomerular filtration rate  
Table 3 
Univariate analysis
HR (95% CI)                                    p-value
Multivariate analysis
HR (95% CI)                                                 p-value
Sex
Male
Female
Reference
1.35 (0.57-2.95)
-
0.480
Age 1.00 (0.96-1.04) 0.963
Pathology
CCC
Non-CCC
Reference
2.49 (1.02-5.54)
-
0.0455
Reference
4.27 (1.30-14.6)
-
0.0173
Karnofsky performance status, %
≥ 80 
< 80
0.25 (0.11-0.68)
Reference
0.0094
-
2.59 (0.63-11.7)
Reference
0.190
-
Time from diagnosis to treatment, days
≥ 365
< 365
Reference
3.14 (1.20-10.7)
-
0.0172
Reference
1.55 (0.24-32.1)
-
0.689
MSKCC
Favorable
Intermediate
Poor
0.41 (0.093-1.26)
Reference
3.28 (1.43-7.38)
0.0011
0.126
-
0.0058
1.51 (0.13-40.4)
Reference
3.19 (0.83-12.2)
0.239
0.760
-
0.0908
Number of metastatic sites
Solitary
Multiple
Reference
2.28 (1.04-5.27)
-
0.0385
Reference
2.61 (0.91-7.91)
-
0.0748
pT stage
pT1-2
pT3-4
Reference
4.48 (1.56-18.9)
-
0.0035
Reference
3.27 (0.84-17.6)
-
0.0917
Sarcopenia
No
Yes
Reference
4.29 (1.72-13.0)
-
0.0012
Reference
2.29 (0.73-8.16)
-
0.157
SMD
High muscle attenuation
Low muscle attenuation
Reference
1.86 (0.82-4.77)
-
0.140
The mGPS
0
1 
2 
0.033 (0.0092-0.10)
0.048 (0.0089-0.20)
Reference
<0.0001
<0.0001
<0.0001
-
0.069 (0.014-0.31)
0.053 (0.0059-0.34)
Reference
0.0012
0.0004
0.0014
-
Serum eGFR level, mL/min/1.73m2 0.98 (0.96-1.01) 0.138
HR, hazard ratio; CI, confidence interval; CCC, clear cell carcinoma; MSKCC, Memorial Sloan-Kettering Cancer Center; SMD, skeletal muscle density; mGPS, 
modified Glasgow prognostic score; eGFR, estimated glomerular filtration rate
Table 3: Univariate and multivariate analyses of overall survival
 
Table 4 
All (n = 71) With sarcopenia (n = 45) Without sarcopenia (n = 26) p-value
Initial dose 
50 mg
37.5 mg
25 mg
21 (29.6%)
35 (49.3%)
15 (21.1%)
11 (24.4%)
21 (46.7%)
13 (28.9%)
10 (38.5%)
14 (53.8%)
2 (7.69%)
0.0920
RDI during first cycle
≥ 75%
< 75% 
38 (53.5%)
33 (46.5%)
21 (46.7%)
24 (53.3%)
17 (65.4%)
9 (34.6%)
0.128
DLT 
With
Without 
36 (50.7%)
35 (49.3%)
23 (51.1%)
22 (48.9%)
13 (50.0%)
13 (50.0%)
0.928
Prevalence of selected toxicities  
Fatigue
Grade 2
Grade 3
HFS 
Grade 2
Grade 3
Hepatic disorder  
Grade 2
Grade 3
Neutropenia
Grade 2
Grade 3
Thrombocytopenia 
Grade 2
Grade 3
Number of patients with grade 2
Number of patients with grade 3
8 (11.3%)
0
5 (7.04%)
0
1 (1.41%)
2 (2.82%)
2 (2.82%)
5 (7.04%)
9 (12.7%)
7 (9.86%)
26 (36.6%)
14 (19.7%)
6 (13.3%)
0
2 (4.44%)
0
0
1 (2.22%) 
2 (4.44%) 
3 (6.67%)
4 (8.89%)
5 (11.1%)
15 (33.3%)
10 (22.2%)
2 (7.69%)
0
3 (11.5%)
0
1 (3.85%)
1 (3.85%) 
0
2 (7.69%) 
5 (19.2%) 
2 (7.69%)
11 (42.3%)
4 (15.4%)
0.469
-
0.260
-
0.186
0.690
0.276
0.871
0.207
0.642
0.450
0.485
RDI during six cycles
≥ 75%
< 75% 
24 (33.8%)
47 (66.2%)
13 (28.9%)
32 (71.1%)
11 (42.3%)
15 (57.7%)
0.302
Treatment after DLT 
Reduction of dose 
Discontinuation of sunitinib
Switching to other targeted agents 
31 (86.1%)
4 (11.1%)
1 (2.78%)
18 (40.0%)
4 (17.4%)
1 (4.35%)
13 (100.0%)
0
0
0.194
Table 4: Comparisons of sunitinib safety and tolerability between sarcopenic and non-sarcopenic patients during the first cycle
RDI, relative dose intensity; DLT, dose-limiting toxicities; HFS, hand-foot syndrome  
Table 5 
All (n = 71) mGPS 1 and 2 (n = 18) mGPS 0 (n = 53) p-value
Initial dose 
50 mg
37.5 mg
25 mg
21(29.6%)
35 (49.3%)
15 (21.1%)
7 (38.9%)
9 (50.0%)
2 (11.1%)
14 (26.4%)
26 (49.1%)
13 (24.5%)
0.396
RDI during first cycle
≥ 75%
< 75% 
38 (53.5%)
33 (46.5%)
8 (44.4%)
10 (55.6%%)
30 (56.6%)
23 (43.4%)
0.372
DLT 
With
Without 
36 (50.7%)
35 (49.3%)
11 (61.1%)
7 (38.9%)
25 (47.2%)
28 (52.8%)
0.307
Prevalence of selected toxicities
Fatigue
Grade 2
Grade 3
HFS 
Grade 2
Grade 3
Hepatic disorder  
Grade 2
Grade 3
Neutropenia
Grade 2
Grade 3
Thrombocytopenia 
Grade 2
Grade 3
Number of patients with grade 2 toxicities 
Number of patients with grade 3 toxicities
8 (11.3%)
0
5 (7.04%)
0
1 (1.41%)
2 (2.82%)
2 (2.82%)
5 (7.04%)
9 (12.7%)
7 (9.86%)
26 (36.6%)
14 (19.7%)
2 (11.1%)
0
2 (11.1%)
0
1 (5.56%)
0
0
0
4 (22.2%)
4 (22.2%)
8 (44.4%)
4 (22.2%)
6 (11.3%)
0
3 (5.66%)
0
0
2 (3.77%)
2 (3.77%)
5 (9.43%)
5 (9.43%)
3 (5.66%)
18 (34.0%)
10 (18.9%)
0.981
-
0.435
-
0.254
0.403
0.403
0.177
0.159
0.0635
0.425
0.757
RDI during six cycles 
≥ 75%
< 75% 
24 (33.8%)
47 (66.2%)
7 (38.9%)
11 (61.1%)
17 (32.1%)
36 (67.9%)
0.774
With DLT All (n = 36) mGPS 1 and 2 (n = 11) mGPS 0 (n = 25)
Treatment after DLT 
Reduction of dose 
Discontinuation of sunitinib
Switching to other targeted agents 
31 (86.1%)
4 (11.1%)
1 (2.78%)
10 (90.9%)
1 (9.09%)
0 
21 (84.0%)
3 (12.0%)
1 (4.00%)
0.763
Table 5 : Comparisons of sunitinib safety and tolerability between mGPS 0 and mGPS 1 and 2
mGPS, modified Glasgow prognostic score; RDI, relative dose intensity; DLT, dose-limiting toxicities; HFS, hand-foot syndrome  
 
